SCHEMBL25839669

SCHEMBL25839669

CCOC(=O)c1c(F)cc(Br)cc1C(=O)OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.48
ALOX5 P09917 6/20 0.47
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
NOTUM Q6P988 1/20 0.40
PTGES O14684 1/20 0.40
TP53 P04637 1/20 0.40
HTT P42858 1/20 0.40
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP3A4 P08684 2/20 0.39
HPGD P15428 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20076067 0.88 NOTUM (0.42) ALOX5NOTUMHTTMAPTTSHR
SCHEMBL23526377 0.87 ALOX5 (0.40) KMT2AALOX5NOTUMPTGESTP53
SCHEMBL29945784 0.87 ALOX5 (0.40) KMT2AALOX5NOTUMPTGESTP53
SCHEMBL22914551 0.86 NR1H2 (0.50) ALOX5NR1H2NR1H3PTGESHTT
SCHEMBL23526095 0.81 NOTUM (0.41) KMT2ANOTUMHTTMAPTTSHR
SCHEMBL24252864 0.78 TSHR (0.46) KMT2ANOTUMHTTMAPTTSHR
SCHEMBL29570702 0.78 NOTUM (0.42) NOTUMMAPTTSHRHSD17B10CA12
SCHEMBL21198962 0.78 NOTUM (0.42) NOTUMMAPTTSHRHSD17B10CA12
SCHEMBL517686 0.77 NOTUM (0.47) NOTUMHTTMAPTTSHRCYP3A4
SCHEMBL21199629 0.77 NOTUM (0.43) KMT2ANOTUMMAPTHSD17B10CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702418-B2 SOS1 inhibitors SOS1, SOS2, SOST KMT2A 3302/4885ALOX5 4146/4885NR1H2 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.